Form 4: Artiva Biotherapeutics CEO Receives Stock Grant
Insider Transaction (Form 4)
Fred Aslan, Chief Executive Officer and a Director of Artiva Biotherapeutics, Inc., reported multiple transactions in common stock on September 10, 2026.
Summary
- Grant/award: acquired 45,000 Common Stock on September 10, 2026; holds 1,494,765 after (Direct).
- Grant/award: acquired 155,000 Employee Stock Option (Right to Buy) on September 10, 2026; holds 155,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Fred Aslan — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-10 | Grant/award | Common Stock | 45,000 | — | — | 1,494,765 |
| 2026-09-10 | Grant/award | Employee Stock Option (Right to Buy) | 155,000 | — | — | 155,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-10 | Grant/award (45,000 shares) |
| 2026-09-10 | Grant/award (155,000 shares) |
Keywords
insider transaction, Form 4, ARTV, Artiva Biotherapeutics, Inc., neutral, Fred Aslan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.